Anixa Biosciences Inc SEC Filings

Anixa Biosciences Chief Executive Officer Amit Kumar reported an open-market purchase of 21,000 shares of Common Stock at $2.50 per share. This transaction increased his direct ownership to 630,812 shares following the trade. The filing reflects a single buy transaction with no accompanying sales or derivative exercises.

Anixa Biosciences reported its quarterly results for the period ended April 30, 2026, remaining a pre-revenue biotech focused on cancer vaccines and CAR‑T therapies. The company posted a net loss attributable to common shareholders of $2.5 million for the quarter and $5.1 million for the six-month period, both modestly improved from the prior year as research and general expenses declined.

Anixa ended April 30, 2026 with $13.7 million in cash, cash equivalents and short‑term investments, down from $15.2 million at October 31, 2025, and believes this will fund operations for at least 12 months. During the six months, it raised $2.9 million via an at‑the‑market stock offering and maintains capacity to sell about $97 million more. The company continues a Phase 1 ovarian cancer CAR‑T trial showing good tolerability with anecdotal signs of efficacy, and completed Phase 1 of its breast cancer vaccine with all primary endpoints met and immune responses in 74% of subjects, preparing now for Phase 2.

Anixa Biosciences, Inc. held its 2026 annual meeting of stockholders on March 10, 2026. A total of 33,379,505 shares of common stock were entitled to vote, and 20,805,324 shares were present in person or by proxy, establishing a quorum.

Stockholders re-elected Dr. Amit Kumar, Dr. Arnold Baskies, Emily Gottschalk, and Lewis H. Titterton, Jr. as directors to serve until the 2027 annual meeting or until successors are elected and qualified. They also approved, on a non-binding, advisory basis, the Company’s executive compensation and ratified the appointment of Haskell & White LLP as independent registered public accounting firm for the fiscal year ending October 31, 2026.

The company filed as an exhibit a management presentation used at the annual meeting, which may also be used in future meetings with investors, analysts, or others.

Anixa Biosciences reported quarterly results for the three months ended January 31, 2026, showing a net loss attributable to common shareholders of $2.565M, improved from $3.184M a year earlier. The company generated no revenue, reflecting its focus on developing cancer vaccines and CAR-T therapies.

Research and development expenses fell to $1.102M and general and administrative expenses to $1.614M, both down from the prior year as certain trial and manufacturing activities tapered. Cash, cash equivalents and short-term investments totaled $14.202M at January 31, 2026, after raising $1.625M through an at-the-market stock offering.

The CAR-T program for ovarian cancer has treated 13 patients in a dose-escalation Phase 1 trial, with treatment reported as well-tolerated across cohorts and several patients living well beyond typical median survival, though the study is primarily designed to assess safety. Anixa’s breast cancer vaccine completed Phase 1 with all primary endpoints met and 74% of subjects showing protocol-defined immune responses, and the company is preparing a Phase 2 trial. Management believes current liquidity will fund operations for at least the next twelve months.

Anixa Biosciences reported early clinical observations from its Phase 1 ovarian cancer CAR-T trial, highlighting encouraging survival in heavily pre-treated patients and a clean safety profile. Twelve women with recurrent ovarian cancer have been treated at four low-dose levels. Seven have lived beyond the expected median survival of about three to four months, including one patient who survived 28 months and several others ranging from 8 to 17 months. No dose-limiting toxicities have been seen so far, allowing regulators to approve a protocol amendment that increases the dose range from 1×10⁵–1×10⁷ CAR-positive cells/kg up to 1×10⁹ cells/kg. The next cohort will receive 1×10⁷ cells/kg with a lymphodepletion regimen to explore whether this boosts CAR-T expansion and activity in this solid tumor setting.

Anixa Biosciences director Arnold M. Baskies reported buying additional company stock. On January 28, 2026, he purchased 10,000 shares of Anixa Biosciences common stock at $3.04 per share. Following this open-market purchase, he directly owns 135,000 shares of the company’s common stock.

Anixa Biosciences, Inc. is asking stockholders to vote at its 2026 Annual Meeting, which will be held virtually on March 10, 2026 at 10:00 a.m. Pacific time. Stockholders of record as of January 13, 2026, when 33,379,505 common shares were outstanding, may vote.

Investors are being asked to elect four directors (Dr. Amit Kumar, Dr. Arnold Baskies, Emily Gottschalk and Lewis H. Titterton Jr.) for one-year terms, approve on a non-binding, advisory basis the compensation of the named executive officers, and ratify Haskell & White LLP as independent registered public accounting firm for the fiscal year ending October 31, 2026.

The Board unanimously recommends voting “FOR” all four director nominees, “FOR” the advisory say‑on‑pay proposal, and “FOR” ratification of the auditor. The proxy explains how to vote by internet, telephone, mail, or at the virtual meeting, and details board committees, governance practices, and executive and director compensation.

Anixa Biosciences, Inc. is an early-stage biotechnology company focused on oncology, developing a CAR-T cell therapy and multiple cancer vaccines rather than generating product revenue. Its lead therapeutic, lira-cel, is a follicle stimulating hormone receptor–targeted CAR-T for ovarian cancer in a Phase 1 dose-escalation trial at Moffitt Cancer Center; four dose cohorts up to 30-times the initial dose have been treated and the therapy has been described as well-tolerated with anecdotal signs of efficacy in heavily pretreated patients.

The company’s breast cancer vaccine, licensed from Cleveland Clinic and targeting α-lactalbumin, completed a 35-participant Phase 1 trial, meeting all primary endpoints and showing protocol-defined immune responses in 74% of subjects with mainly injection-site irritation as the key adverse event. Final data were presented in December 2025 and will guide planned Phase 2, including a potential Keytruda combination study. Anixa is also advancing an ovarian cancer vaccine within the NCI PREVENT program and an early discovery effort for lung, colon and prostate cancer vaccines.

Financially, as of October 31, 2025 Anixa reported an accumulated deficit of approximately $251,677,000, fiscal 2025 losses of about $11,028,000, cash, cash equivalents and short-term investments of roughly $15,174,000, and working capital of about $13,920,000. Management believes existing resources can fund operations for at least 12 months, but the company expects to continue incurring losses, remains pre-revenue in therapeutics and vaccines, and may need substantial additional capital, including under a current at-the-market equity program that permits up to $100 million of future common stock sales.

Michael Catelani, an insider of Anixa Biosciences, Inc., has filed an amended Schedule 13D reporting increased beneficial ownership of the company’s common stock. He now beneficially owns 2,468,103 shares of Anixa common stock, representing 7.0% of the outstanding shares. This total consists of 44,500 shares of common stock held directly and 2,423,603 shares issuable upon exercise of stock options that are exercisable within 60 days.

The filing notes that this ownership level has risen from 5.25% previously, driven by market purchases, vesting of existing stock options, and a change in which options become exercisable within 60 days. The triggering event was the January 5, 2026 grant to Mr. Catelani of a stock option to purchase up to 175,000 shares of common stock at an exercise price of $3.18 per share. He holds sole voting and dispositive power over all of these shares, and no other persons are identified as having rights to dividends or sale proceeds.